Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Medicamen Organics IPO
Price Band
₹32.0–34.0
Issue Size
₹10.54 Cr
Lot Size
4,000 shares
Min Investment
₹136,000
GMP
+₹70.0 (205.88%)
Issue Price
₹34.0
Subject to Sauda
₹212800
Paid only if allotted
Medicamen Organics IPO AI Summary
- Medicamen Organics IPO is listed on NSE SME in the Pharmaceuticals sector.
- Price band: ₹32.0–₹34.0 per share, lot size 4,000 shares (min. investment ₹136,000).
- Subscription window: 21 Jun–25 Jun 2024, listing on 28 Jun 2024.
- Current GMP is +₹70.0 (205.88%), an estimated listing price of ₹104 — unofficial and can change daily.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Medicamen Organics IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 25 Jun 2024 — not a current signal.
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Medicamen Organics IPO Grey Market Premium (GMP) Today
GMP
+₹70.0
GMP %
+205.88%
Est. Listing
₹104.0
Updated: 25 Jul 2026 14:05
About the Company
Medicamen Organics Limited was incorporated in 1995 and develops, manufactures, and distributes pharmaceutical dosages including generic dosages in the form of tablets, capsules, oral liquids, ointments, gels, syrups, suspensions and dry powders for the Government (including State Governments and Central Governments) and private entities as a contract manufacturer/third party manufacturer. The company's product list comprises 84 products and offers a wide range of drugs such as antibacterial, antidiarrheal, antifungal, antimalarial, antidiabetic, proton pump inhibitors, antihistamines, antihypertensive drugs, lipid preparations, antiparasitics, multivitamin preparations, multimineral and non-steroidal anti-inflammatory drugs (NSAIDS). The company's products are marketed throughout India as well as in African, CIS, and South East Asian countries such as Congo, Benin, Kameg, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Togo, Burundi, Kyrgyzstan and Kenya through third-party distributors. The company has two WHO-GMP-approved manufacturing facilities in Haridwar, Uttarakhand, covering an area of 21,536 Sq. Ft. As on September 30, 2023, the company has entered into contract manufacturing with 38 domestic partners and 12 merchant exporters. As of September 30, 2023, the company employed a total of 116 people.
Company Financials (₹ Cr)
As of 2023-09-30
| Period Ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
|---|---|---|---|---|
| Assets | 38.58 | 32.12 | 27.07 | 26.34 |
| Total Income | 25.29 | 22.96 | 21.19 | 25.06 |
| Profit After Tax | 2.40 | 0.96 | 0.09 | 0.30 |
| NET Worth | 15.18 | 8.52 | 7.56 | 7.47 |
| Reserves and Surplus | 6.58 | 2.52 | 1.56 | 1.47 |
| Total Borrowing | 12.66 | 11.80 | 10.25 | 9.59 |
Key Ratios
EPS
₹1.11
NAV
₹17.66
ROE
19.90%
ROCE
14.50%
RoNW
15.83%
P/B Value
2.39
P/E Ratio
30.53
Market Cap
₹39.78 Cr
PAT Margin
9.51%
Debt/Equity
0.83
Peer Comparison
| Company | NAV | RoNW | P/E (x) | EPS Basic | EPS Diluted |
|---|---|---|---|---|---|
| Zenotech Laboratories Ltd. | 14.2 | 14.08% | 38.76 | 1.9 | 1.9 |
| Cian Healthcare Ltd | 22.4 | 1.75% | 53.84 | 0.43 | 0.43 |
| Brooks Laboratories Ltd. | 30.1 | -28.26% | 10.6 | -12.57 | -12.57 |
| Medicamen Organics Limited This IPO | 17.66 | 15.83% | — | 3.18 | 3.18 |
Promoters
Bal Kishan Gupta
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Funding of expenses proposed to be incurred towards Product registration in the international markets 3.00 2 Plant updation and increase in production capacity 2.25 3 Funding working capital requirements of our Company 4.00 4 General corporate purpose 0.39
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total income was ₹21.19 Cr in the year ending 31 Mar 2022, increasing to ₹22.96 Cr by 31 Mar 2023, and further rising to ₹25.29 Cr by 31 Mar 2024. This shows a consistent upward trend in revenue over the periods.
Profit Trend
Profit after tax was ₹0.09 Cr in the year ending 31 Mar 2022, which rose to ₹0.96 Cr by 31 Mar 2023, and further increased to ₹2.40 Cr by 31 Mar 2024. This indicates a significant growth in profitability over the periods.
Valuation
Priced at roughly 30.53 times trailing earnings, versus peers trading at a P/E range of 10.6 to 53.84.
Grey Market Premium, Explained
The Grey Market Premium (GMP) is an indicator of the expected listing price of an IPO. It reflects the demand for the shares before they are officially listed on the stock exchange. A higher GMP suggests strong demand and potential listing gains, while a lower GMP indicates weaker demand.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their investment strategy and risk tolerance, considering the company's growth potential and market conditions.
Who May Want to Wait
Investors who prefer stable, established companies with consistent earnings may want to avoid IPOs like this, which can be subject to market fluctuations and operational risks.
Listing Gains — The Risk
Listing-day gains can be unpredictable. Factors such as market sentiment, overall economic conditions, and company performance can influence the stock price on the day of listing. Investors should be aware that while high GMP may suggest potential gains, it does not guarantee a profit.
This evaluation is generated from Medicamen Organics's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Medicamen Organics IPO GMP today?
Medicamen Organics IPO GMP today is +₹70.0 (205.88%), indicating an estimated listing price of ₹104. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Medicamen Organics IPO?
The price band of Medicamen Organics IPO is ₹32.0–₹34.0 per share.
When does Medicamen Organics IPO open and close?
Medicamen Organics IPO opens on 21 June 2024 and closes on 25 June 2024.
When does Medicamen Organics IPO list on the stock exchange?
Medicamen Organics IPO listed on 28 June 2024 at ₹104.0.
What is the lot size for Medicamen Organics IPO?
The lot size for Medicamen Organics IPO is 4000 shares, requiring a minimum investment of ₹136,000.
What is the price band for the IPO?
The price band for the IPO is ₹32.0 to ₹34.0.
What is the minimum investment required?
The minimum investment required is ₹136,000.
What is the lot size for this IPO?
The lot size for this IPO is 4,000 shares.
When is the listing date?
The listing date is scheduled for June 28, 2024.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected premium of the IPO shares over the issue price in the grey market.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
21 Jun 2024
Close
25 Jun 2024
Allotment
26 Jun 2024
Listing
28 Jun 2024
Similar IPOs in Pharmaceuticals
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Medicamen Organics?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.